Developing anti-TNF and biologic agents
Open Access
- 9 July 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (8), 1351-1353
- https://doi.org/10.1093/rheumatology/ker235
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritisNature Reviews Rheumatology, 2009
- Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid ArthritisThe Journal of Rheumatology, 2009
- Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics RegisterAnnals Of The Rheumatic Diseases, 2008
- The safety of anti-tumour necrosis factor therapy in rheumatoid arthritisCurrent Opinion in Rheumatology, 2008
- The effect of methotrexate and anti–tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON‐YEARS of observationArthritis & Rheumatism, 2007
- Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritisArthritis & Rheumatism, 2006
- The PREMIER study: A multicenter, randomized, double‐blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatmentArthritis & Rheumatism, 2005
- TNF-blocking agents and tuberculosis: new drugs illuminate an old topicRheumatology, 2005
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritisThe Lancet, 1994